Fundraising FoxBiotech Startups
11,050 companies tagged Biotech, with their investors and founders.
RECELL is an FDA-approved autologous skin cell suspension device for treating burns, trauma, and surgical wounds by harvesting a patient's own skin cells and applying them to accelerate healing and reduce the need for large skin grafts. The technology serves hospital systems and wound care clinicians treating severe burn and trauma patients.
0 investors
0 investors
AVM Biotechnology develops AVM0703, a proprietary concentrated dexamethasone formulation designed to trigger the release and production of specialized immune cells (gamma delta and invariant TCR+ bispecific T lymphocytes and NK T-like cells) as a treatment approach for various diseases. The company operates in the biotechnology and immunotherapy space, with a therapeutic candidate in pre-clinical and clinical stages.
0 investors
0 investors
0 investors
0 investors
0 investors
AXIM Biotechnologies is a research and development company that develops rapid point-of-care diagnostic tests for ophthalmological conditions, targeting ocular biomarkers linked to aqueous deficient dry eye disease and allergic conjunctivitis. Its tests are designed to help eye-care physicians detect and quantify these biomarkers.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
AyuVis develops novel small-molecule immunotherapies with a unique mode of action to fight inflammation and infection. Founded in 2014, the company focuses on drug discovery and clinical development in areas including neonatal immunology and infectious disease.
0 investors
0 investors
0 investors
0 investors
0 investors
B1 Health builds AI-native, agentic software for biopharma and CRO enterprises, embedding governed AI agent teams into workflows for protocol and clinical study report writing, competitive intelligence, KOL identification, integrated evidence generation, patient data infrastructure, and project management. Its outputs are AI-generated and validated by human experts before use.
0 investors
0 investors
0 investors
0 investors